Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer

Laboratory Investigation

Volumn 94, Issue 1, 2014, Pages 98-106

  Brown, Jason R ^a   Digiovanna, Michael P ^a   Killelea, Brigid ^a   Lannin, Donald R ^a   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; field of view; hotspot; neoadjuvant chemotherapy; pathological complete response; predictive biomarkers; quantitative immunofluorescence

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AQUA SCORE; AREA UNDER THE CURVE; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER SIZE; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR INVASION;

ADULT; AGED; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HISTOCYTOCHEMISTRY; HUMANS; KI-67 ANTIGEN; LOGISTIC MODELS; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84891506225     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.128     Document Type: Article

References (51)

1. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. J Clin Oncol 2006;24:1940-1949
2. Buchholz TA, Lehman CD, Harris JR, et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: A National Cancer Institute conference. J Clin Oncol 2008;26:791-797
3. Bafaloukos D. Neo-Adjuvant therapy in breast cancer. Ann Oncol 2005;16(Suppl 2):ii174-ii181
4. Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations. J Clin Oncol 2003;21:2600-2608
5. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24: 2019-2027
6. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-4174
7. Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy: The MD Anderson cancer center experience. J Clin Oncol 2004;22:2303-2312
8. van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224-4237
9. Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999;10:47-52
10. Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002;95:681-695
11. Heys SD, Hutcheon AW, Sarkar TK, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002;3(Suppl 2):S69-S74
12. Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6. Eur J Cancer 1994;30A:645-652
13. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-2685
14. Cleator SJ, Makris A, Ashley SE, et al. Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann Oncol 2005;16:267-272
15. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30:1796-1804
16. Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 2008;26:814-819
17. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778-785
18. Valero V, Perez E, Dieras V. Doxorubicin and taxane combination regimens for metastatic breast cancer: Focus on cardiac effects. Semin Oncol 2001;28(4 Suppl 12):15-23
19. Smith RE, Anderson SJ, Brown A, et al. Phase II trial of doxorubicin/ docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: Results from NSABP trial BP-58. Clin Breast Cancer 2002;3:333-340
20. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24: 1037-1044
21. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA 2007;104:13086-13091
22. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004;22:2284-2293
23. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790-800
24. Staunton JE, Slonim DK, Coller HA, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 2001;98: 10787-10792
25. Hatzis C, Pusztai L, Valero V, et al. A genomic predictor of response and survival following taxane-Anthracycline chemotherapy for invasive breast cancer. JAMA 2011;305:1873-1881
26. Popovici V, Chen W, Gallas BG, et al. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res 2010;12:R5
27. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-Associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715
28. Verheijen R, Kuijpers HJ, van Driel R, et al. Ki-67 detects a nuclear matrix-Associated proliferation-related antigen. II. Localization in mitotic cells and association with chromosomes. J Cell Sci 1989; 92(Pt 4):531-540
29. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005;23:7212-7220
30. Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki67 in breast cancer: Recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011;103:1656-1664
31. Luporsi E, Andre F, Spyratos F, et al. Ki-67: Level of evidence and methodological considerations for its role in the clinical management of breast cancer: Analytical and critical review. Breast Cancer Res Treat 2012;132:895-915
32. Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: Prognostic and predictive potential. Lancet Oncol 2010;11: 174-183
33. Penault-Llorca F, Abrial C, Raoelfils I, et al. Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclooxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 2008;13:1235-1245
34. Bozzetti C, Musolino A, Camisa R, et al. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: The role of anthracycline dose intensity. Am J Clin Oncol 2006;29:171-177
35. Keam B, Im SA, Lee KH, et al. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 2011;13:R22
36. Miglietta L, Vanella P, Canobbio L, et al. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis. Oncology 2010;79:255-261
37. Fasching PA, Heusinger K, Haeberle L, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 2011;11:486
38. Bottini A, Berruti A, Bersiga A, et al. Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br J Cancer 2001;85:1106-1112
39. Jones RL, Salter J, A'Hern R, et al. Relationship between oestrogen receptor status and proliferation in predicting response and long-Term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2010;119:315-323
40. Tanei T, Shimomura A, Shimazu K, et al. Prognostic significance of Ki6& index after neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol 2011;37:155-161
41. Cattoretti G, Becker MH, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-363
42. Neumeister VM, Anagnostou V, Siddiqui S, et al. Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. J Natl Cancer Inst 2012;104: 1815-1824
43. Bordeaux J, Welsh A, Agarwal S, et al. Antibody validation. Biotechniques 2010;48:197-209
44. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323-1327
45. Dolled-Filhart M, Gustavson M, Camp RL, et al. Automated analysis of tissue microarrays. Methods Mol Biol 2010;664:151-162
46. Mohammed ZM, McMillan DC, Elsberger B, et al. Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer 2012;106:383-388
47. Fasanella S, Leonardi E, Cantaloni C, et al. Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagn Pathol 2011;6(Suppl 1):S7
48. Stuart-Harris R, Caldas C, Pinder SE, et al. Proliferation markers and survival in early breast cancer: A systematic review and meta-Analysis of 85 studies in 32,825 patients. Breast 2008;17:323-334
49. Voros A, Csorgo E, Nyari T, et al. An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assessment on core biopsies of breast cancer patients and its potential clinical implications. Pathobiology 2012;80:111-118
50. Romero Q, Bendahl PO, Klintman M, et al. Ki67 proliferation in core biopsies versus surgical samples-A model for neo-Adjuvant breast cancer studies. BMC Cancer 2011;11:341
51. Niikura N, Iwamoto T, Masuda S, et al. Immunohistochemical Ki6& labeling index has similar proliferation predictive power to various gene signatures in breast cancer. Cancer Sci 2012;103:1508-1512.